List of Excipients in Branded Drug DELFLEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Fresenius Medical Care de Mexico SA de CV	DELFLEX	dextrose monohydrate, sodium chloride, sodium lactate, calcium chloride, magnesium chloride	46163-206	WATER
Fresenius Medical Care de Mexico SA de CV	DELFLEX	dextrose monohydrate, sodium chloride, sodium lactate, calcium chloride, magnesium chloride	46163-209	WATER
Fresenius Medical Care North America	DELFLEX	dextrose monohydrate, sodium chloride, sodium lactate, calcium chloride, magnesium chloride	49230-191	WATER

DELFLEX Excipient Strategy and Commercial Opportunities in Peritoneal Dialysis

Last updated: September 26, 2026

DELFLEX is a dextrose-based peritoneal dialysis solution used for continuous ambulatory peritoneal dialysis and automated peritoneal dialysis. Its formulation strategy relies on dextrose as the osmotic agent and a tightly controlled electrolyte system containing sodium chloride, sodium lactate, calcium chloride, magnesium chloride and water for injection. The strongest commercial opportunities are in biocompatible dialysis fluids, differentiated osmotic agents, dual-chamber packaging, supply-chain efficiency and private-label manufacturing. The principal constraints are clinical equivalence requirements, sterile manufacturing, reimbursement economics and competition from established products such as Baxter’s DIANEAL and EXTRANEAL.

What is DELFLEX and how does its formulation work?

DELFLEX is a sterile peritoneal dialysis solution containing dextrose in several concentrations. The dextrose concentration determines the approximate osmotic strength and supports removal of excess fluid from the peritoneal cavity.

Formulation characteristic	Commercial and technical role
Active osmotic agent	Dextrose monohydrate
Electrolytes	Sodium chloride, sodium lactate, calcium chloride dihydrate and magnesium chloride hexahydrate
Diluent	Water for injection
Administration route	Intraperitoneal
Primary use	Peritoneal dialysis
Osmotic variants	Commonly marketed as 1.5%, 2.5% and 4.25% dextrose strengths
Dosage form	Sterile dialysis solution in flexible containers
Regulatory category	Prescription dialysis product regulated by FDA

The solution is designed to approximate physiologic electrolyte conditions while creating an osmotic gradient across the peritoneal membrane. The lactate component acts as a buffer precursor. Calcium and magnesium concentrations must remain within controlled ranges because both affect patient safety, membrane function and compatibility with dialysis prescriptions. The FDA-approved labeling identifies the composition, indications, warnings, container requirements and administration limitations for DELFLEX products.[1]

What excipients are used in DELFLEX?

DELFLEX uses a relatively limited excipient system. The formulation does not depend on conventional tablet excipients, surfactants or preservatives.

Component	Formulation function	Commercial significance
Dextrose monohydrate	Osmotic agent	Determines fluid removal and product segmentation by strength
Sodium chloride	Provides sodium and chloride ions	Supports electrolyte balance
Sodium lactate	Buffer precursor and electrolyte source	Supports control of solution acidity and physiologic compatibility
Calcium chloride dihydrate	Calcium replacement	Requires tight control for safety and dialysis performance
Magnesium chloride hexahydrate	Magnesium replacement	Supports electrolyte balance
Water for injection	Sterile vehicle	Determines manufacturing, sterilization and container requirements

The use of dextrose creates a familiar and scalable platform, but it also creates clinical and commercial limitations. Repeated exposure to high-glucose dialysis fluids is associated with glucose absorption, metabolic burden and potential effects on the peritoneal membrane. These limitations create demand for products using alternative osmotic agents or more physiologic buffer systems.[2]

How strong is the DELFLEX formulation strategy?

DELFLEX has a technically efficient formulation strategy but limited differentiation at the ingredient level. Its principal strengths are manufacturing simplicity, established clinical use and compatibility with standard peritoneal dialysis practice.

Strengths of the excipient system

The formulation has five commercial advantages:

1. It uses ingredients with extensive historical use in dialysis solutions.
2. Dextrose provides predictable osmotic activity and allows multiple fluid-removal strengths.
3. The electrolyte profile is familiar to nephrologists and dialysis providers.
4. The solution can be manufactured at scale using established sterile-fluid processes.
5. The formulation can be supplied in multiple container sizes and prescription strengths.

Limitations of the excipient system

The same formulation creates several constraints:

• Dextrose is absorbed systemically and can affect glucose exposure.
• High-dextrose solutions can contribute to hyperglycemia and increased metabolic load.
• Lactate-based buffering may be less differentiated than bicarbonate or bicarbonate/lactate systems.
• The formulation is vulnerable to comparison with icodextrin, amino-acid and neutral-pH products.
• Container and sterilization requirements can affect product stability and manufacturing cost.

The product therefore has a stronger manufacturing and supply-chain position than an ingredient-level intellectual-property position.

What formulations compete with DELFLEX?

DELFLEX competes across three formulation categories: conventional dextrose solutions, alternative osmotic solutions and biocompatible-buffer solutions.

Product category	Representative example	Differentiation from DELFLEX
Dextrose/lactate solution	DELFLEX, DIANEAL	Established platform, multiple osmotic strengths
Icodextrin solution	EXTRANEAL	Longer dwell fluid removal and lower glucose exposure
Amino-acid solution	NUTRINEAL	Provides amino acids while supplying osmotic activity
Bicarbonate/lactate solution	Physioneal and comparable products	More physiologic buffer approach and potentially improved tolerability
Neutral-pH, low-degradation-product solution	Certain biocompatible platforms	Reduced exposure to glucose degradation products

Baxter’s DIANEAL is the most direct reference product for conventional dextrose peritoneal dialysis solutions. Baxter’s EXTRANEAL uses icodextrin, while NUTRINEAL uses amino acids as the principal osmotic ingredient. These products compete on clinical profile, prescription flexibility and patient tolerability rather than only on price.[3]

What commercial opportunities exist for DELFLEX excipients?

Can DELFLEX support a lower-cost generic or private-label strategy?

Yes. The formulation uses established pharmaceutical ingredients and does not require a novel excipient platform. A lower-cost strategy could focus on:

• Procurement of dextrose and electrolyte salts at scale.
• Regional sterile-fluid manufacturing.
• Standardized container formats.
• Reduced product variation across markets.
• Contract manufacturing for dialysis providers and hospital systems.
• Private-label supply agreements.

The principal barrier is not ingredient availability. It is the cost and technical complexity of validated aseptic or terminal-sterilization operations, container integrity testing and long-term supply reliability.

Can alternative osmotic agents create a premium product?

The most commercially relevant alternatives are icodextrin and amino acids. Icodextrin is a glucose polymer that can support sustained ultrafiltration during long dwells. Amino-acid solutions can provide a nutritional component but require careful patient selection and monitoring.

A differentiated product could use:

• Icodextrin for long-dwell prescriptions.
• Amino acids for selected patients with nutritional needs.
• Lower-dextrose or mixed-osmotic regimens.
• Bicarbonate/lactate buffering.
• Reduced glucose degradation products.
• Neutral-pH packaging systems.

These opportunities are clinically more differentiated than reformulating conventional dextrose concentrations.

Is there an opportunity in dual-chamber or multi-chamber bags?

Yes. Multi-chamber packaging can separate chemically incompatible components until administration. It can support:

• Bicarbonate-containing solutions.
• Improved pH control.
• Reduced degradation products.
• Extended shelf life.
• Combination electrolyte systems.
• On-demand mixing before infusion.

The tradeoff is higher packaging cost, more complex validation and greater risk of manufacturing defects. The commercial case is strongest where improved biocompatibility or shelf life supports a price premium or formulary preference.

What manufacturing and intellectual-property barriers affect DELFLEX?

The principal barriers are manufacturing and regulatory rather than basic composition patents.

Sterile manufacturing requirements

Peritoneal dialysis solutions are high-volume sterile products. Manufacturing controls must address:

• Bioburden and endotoxin limits.
• Container-closure integrity.
• Particulate control.
• Sterility assurance.
• Stability under shipping and storage conditions.
• Compatibility between solution and container.
• Extractables and leachables.
• Accurate fill volume and concentration.

Flexible bags must withstand handling, transport and administration without leakage or loss of sterility. This creates a substantial operational barrier for new entrants.

Formulation and process know-how

Commercial differentiation may be protected through process and packaging know-how involving:

• Heating cycles.
• pH adjustment.
• Glucose degradation control.
• Bag-film selection.
• Overpouch design.
• Port and connector configuration.
• In-line mixing.
• Shelf-life optimization.

These protections may be commercially important even where the basic electrolyte composition is well established.

Patent position

No conclusion about active DELFLEX composition patents, Orange Book listings or enforceable formulation claims should be drawn without a current review of FDA records, USPTO records, assignment data and litigation databases. Conventional dextrose-electrolyte dialysis formulations generally face limited composition-level exclusivity because the ingredients and their therapeutic use have long histories. The more defensible IP opportunities are likely to involve packaging, manufacturing processes, buffer systems, stability improvements and differentiated osmotic compositions.

What is the FDA and Orange Book status of DELFLEX?

DELFLEX is regulated as a prescription peritoneal dialysis solution. FDA labeling governs its concentration, composition, administration and warnings.[1]

An Orange Book analysis should distinguish between:

• FDA approval status.
• Product listing and National Drug Code records.
• Patent listing under the applicable FDA framework.
• Regulatory exclusivity.
• Device or container claims that may not appear as conventional drug patents.
• State and federal purchasing status.

The presence or absence of an Orange Book-listed patent does not determine whether a competitor faces manufacturing, regulatory or commercial barriers. A competing product may still require a full regulatory submission, comparative clinical support and validated sterile production.

When does DELFLEX lose exclusivity and when can generics launch?

A precise DELFLEX exclusivity date cannot be stated from the product name alone. Generic or follow-on entry depends on the applicable FDA approval pathway, any listed patents, regulatory exclusivity and the competitor’s product-specific approval date.

For a conventional dextrose dialysis solution, the likely entry model is a competing sterile prescription product rather than a traditional oral solid generic. The launch sequence may include:

Stage	Commercial question
Formulation development	Is the electrolyte and osmotic profile equivalent?
Container development	Does the bag maintain sterility and stability?
Regulatory submission	Is the product eligible for an abbreviated pathway or does it require additional clinical support?
FDA review	Are composition, manufacturing and labeling acceptable?
Commercial preparation	Is supply sufficient for dialysis providers?
Market entry	Can the entrant secure contracts and reimbursement support?

A Paragraph IV challenge would be relevant only if an applicable listed patent creates a barrier to approval. For an established dialysis solution, the more material risks may be product quality, supply reliability, bioequivalence or clinical comparability rather than patent litigation.

What patent litigation and settlement risks affect DELFLEX?

The key litigation risks are likely to arise from later-generation technologies rather than the basic dextrose formulation. Relevant dispute areas include:

• Bag and connector design.
• Multi-chamber packaging.
• Neutral-pH formulations.
• Glucose degradation reduction.
• Icodextrin composition and use.
• Bicarbonate/lactate buffering.
• Manufacturing and sterilization processes.
• Trade dress and product presentation.

No specific DELFLEX-related Paragraph IV litigation, settlement agreement or active patent case is identified here. A current litigation search is required before relying on a conclusion about freedom to operate.

How does DELFLEX compare with competing peritoneal dialysis products?

Factor	DELFLEX	DIANEAL	EXTRANEAL	NUTRINEAL
Primary osmotic agent	Dextrose	Dextrose	Icodextrin	Amino acids
Main use case	Standard dialysis prescriptions	Standard dialysis prescriptions	Long dwell and sustained ultrafiltration	Selected patients requiring amino-acid solution
Ingredient differentiation	Low to moderate	Low to moderate	High	High
Manufacturing complexity	Moderate	Moderate	Higher	Higher
Price competition exposure	High	High	Lower if clinically differentiated	Lower if clinically differentiated
Key commercial risk	Commodity competition	Commodity competition	Clinical selection and reimbursement	Patient selection and reimbursement

DELFLEX is best positioned where providers value established dextrose solutions, supply continuity and competitive pricing. It is less differentiated in premium segments where clinicians prioritize reduced glucose exposure, alternative osmotic mechanisms or improved buffer systems.

What revenue exposure and market opportunities exist?

Product-specific DELFLEX revenue is not reliably available from public sources. Commercial analysis should therefore use market-level indicators rather than assign unsupported revenue estimates.

The most actionable opportunities are:

1. Cost leadership in standard dextrose solutions.
2. Regional supply contracts with dialysis networks.
3. Private-label manufacturing.
4. Portfolio expansion into icodextrin or amino-acid solutions.
5. Bicarbonate/lactate and neutral-pH formulations.
6. Improved bag systems with lower shipping weight or reduced overpouch materials.
7. Supply agreements designed to reduce dialysis-center stockouts.
8. Emerging-market production using local sterile manufacturing capacity.

The greatest commercial value is likely to come from a portfolio rather than from a single conventional dextrose product. A DELFLEX-centered portfolio could use standard dextrose bags as the volume product and differentiated osmotic or biocompatible formulations as higher-margin products.

Key Takeaways

• DELFLEX is a dextrose-based peritoneal dialysis solution with sodium chloride, sodium lactate, calcium chloride, magnesium chloride and water for injection.
• Its excipient system is established, scalable and clinically familiar but has limited ingredient-level differentiation.
• The strongest commercial advantages are manufacturing efficiency, supply reliability and competitive pricing.
• The strongest innovation opportunities involve icodextrin, amino acids, bicarbonate/lactate buffering, neutral-pH systems and multi-chamber packaging.
• Sterile manufacturing, container integrity, stability and regulatory approval are more significant barriers than basic ingredient availability.
• A precise patent expiration, Orange Book or Paragraph IV assessment requires product-specific FDA and patent-record verification.
• The most attractive strategy is a portfolio approach combining conventional dextrose solutions with differentiated dialysis fluids.

FAQs

Is DELFLEX an active pharmaceutical ingredient or a finished dialysis product?

DELFLEX is a finished sterile peritoneal dialysis product. Dextrose is the principal osmotic ingredient, while the electrolyte salts and water form the supporting formulation system.

Can DELFLEX be reformulated with glycerol or polyethylene glycol?

A reformulation with another osmotic agent would create a new product-development program. It would require assessment of osmotic performance, membrane compatibility, systemic absorption, toxicity, stability and FDA approval requirements.

Are DELFLEX ingredients difficult to source?

The individual ingredients are generally established pharmaceutical materials. The difficult part is producing and packaging a sterile, high-volume solution with validated stability and container integrity.

Does DELFLEX have a biosimilar risk?

No. Biosimilar rules apply to biological products. DELFLEX is a sterile small-molecule dialysis solution, so its competitive risk comes from generic, follow-on or therapeutically comparable products rather than biosimilars.

What is the best premium positioning for a DELFLEX successor?

The strongest premium positioning would likely involve reduced glucose exposure, improved buffer physiology, lower glucose degradation products, longer-dwell ultrafiltration or a packaging system that improves stability and clinical convenience.

References

1. U.S. Food and Drug Administration. (n.d.). DELFLEX dextrose peritoneal dialysis solution: Prescribing information. FDA and DailyMed labeling records.

2. U.S. Food and Drug Administration. (2023). Guidance for industry: Container closure systems for packaging human drugs and biologics. FDA.

3. Baxter Healthcare Corporation. (n.d.). DIANEAL, EXTRANEAL and NUTRINEAL peritoneal dialysis solutions: Prescribing information. FDA and DailyMed labeling records.